Download MendeleyFirst-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy.
Angeli, A., Micheli, L., Carta, F., Ferraroni, M., Pirali, T., Fernandez Carvajal, A., Ferrer Montiel, A., Di Cesare Mannelli, L., Ghelardini, C., Supuran, C.T.(2023) J Med Chem 66: 1616-1633
- PubMed: 36626645 Search on PubMedSearch on PubMed Central
- DOI: https://doi.org/10.1021/acs.jmedchem.2c01911
- Primary Citation Related Structures:
8BJX, 8BOE - PubMed Abstract:
Here, we report for the first time a series of compounds potentially useful for the management of oxaliplatin-induced neuropathy (OINP) able to modulate the human Carbonic Anhydrases (hCAs) as well as the Transient Receptor Potential Vanilloid 1 (TRPV1). All compounds showed effective in vitro inhibition activity toward the main hCAs involved in such a pathology, whereas selected items reported moderate agonism of TRPV1. X-ray crystallographic experiments assessed the binding modes of the two enantiomers ( R )- 37a and ( S )- 37b within the hCA II cleft. Although the tails assumed diverse orientations, no appreciable effects were observed for their hCA II affinity. Similarly, the activity of ( R )- 39a and ( S )- 39b on TRPV1 was not influenced by the stereocenters. In vivo evaluation of the most promising derivatives ( R )- 12a , ( R )- 37a , and the two enantiomers ( R )- 39a , ( S )- 39b revealed antihypersensitivity effects in a mouse model of OINP with potent and persistent effect up to 75 min after administration.
- NEUROFARBA Department, Sezione di Scienze Farmaceutiche, University of Florence, via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy.
Organizational Affiliation:
